RÉSUMÉ
BACKGROUND: Individuals with diabetes exhibit a higher risk of cardiovascular disease and mortality compared to healthy individuals. Following a transient ischemic attack (TIA) the risk of stroke and death increase further. Physical activity engagement after a TIA is an effective way of secondary prevention. However, there's a lack of research on how individuals with diabetes modify physical activity levels and how these adjustments impact survival post-TIA. This study aimed to determine the extent to which individuals with diabetes alter their physical activity levels following a TIA and to assess the impact of these changes on mortality. METHODS: This was a nationwide longitudinal study, employing data from national registers in Sweden spanning from 01/01/2003 to 31/12/2019. Data were collected 2 years retro- and prospectively of TIA occurrence, in individuals with diabetes. Individuals were grouped based on decreasing, remaining, or increasing physical activity levels after the TIA. Cox proportional hazards models were fitted to evaluate the adjusted relationship between change in physical activity and all-cause, cardiovascular, and non-cardiovascular mortality. RESULTS: The final study sample consisted of 4.219 individuals (mean age 72.9 years, 59.4% males). Among them, 35.8% decreased, 37.5% kept steady, and 26.8% increased their physical activity after the TIA. A subsequent stroke occurred in 6.7%, 6.4%, and 6.1% of individuals, while death occurred in 6.3%, 7.3%, and 3.7% of individuals, respectively. In adjusted analyses, participants who increased their physical activity had a 45% lower risk for all-cause mortality and a 68% lower risk for cardiovascular mortality, compared to those who decreased their physical activity. CONCLUSIONS: Positive change in physical activity following a ΤΙΑ was associated with a reduced risk of mortality. Increased engagement in physical activity should be promoted after TIA, thereby actively supporting individuals with diabetes in achieving improved health outcomes.
Sujet(s)
Diabète , Exercice physique , Accident ischémique transitoire , Enregistrements , Comportement de réduction des risques , Humains , Accident ischémique transitoire/mortalité , Accident ischémique transitoire/diagnostic , Accident ischémique transitoire/prévention et contrôle , Accident ischémique transitoire/épidémiologie , Mâle , Femelle , Sujet âgé , Suède/épidémiologie , Études longitudinales , Appréciation des risques , Adulte d'âge moyen , Diabète/diagnostic , Diabète/mortalité , Diabète/épidémiologie , Sujet âgé de 80 ans ou plus , Facteurs temps , Facteurs de risque , Accident vasculaire cérébral/mortalité , Accident vasculaire cérébral/diagnostic , Accident vasculaire cérébral/épidémiologie , Accident vasculaire cérébral/prévention et contrôle , Prévention secondaire , Résultat thérapeutique , Facteurs de protection , Études rétrospectives , Cause de décès , RécidiveRÉSUMÉ
BACKGROUND: Sneddon syndrome is an occlusive vasculopathy that presents clinically with generalized livedo racemosa on the skin and transient ischemic attacks, strokes, and cognitive or motor deficits in the central nervous system. Antiplatelet or anticoagulant therapy is recommended. Due to the limited therapeutic efficacy and the resulting serious complications, we propose combination therapy with additional infusion cycles of alprostadil and captopril and report initial long-term results. PATIENTS AND METHODS: We performed a systematic retrospective analysis of all patients with primary Sneddon syndrome who received combination therapy in our clinic between 1995 and 2020. Therapeutic outcomes were evaluated using descriptive statistics compared to historical controls receiving monotherapy. We also analyzed the event rate of complications when combination therapy was discontinued. RESULTS: During the 99.7 patient-years of follow-up, there were no transient ischemic attacks and the stroke rate dropped to 0.02 per patient-year. In comparison, the rates of transient ischemic attacks and strokes in the historical controls ranged from 0.08 to 0.035 per patient-year. After discontinuation of alprostadil therapy, eight events occurred in three patients. CONCLUSIONS: Combination therapy reduces the long-term incidence of ischemic events in patients with primary Sneddon syndrome.
Sujet(s)
Alprostadil , Association de médicaments , Syndrome de Sneddon , Humains , Femelle , Études rétrospectives , Mâle , Syndrome de Sneddon/épidémiologie , Syndrome de Sneddon/traitement médicamenteux , Adulte d'âge moyen , Adulte , Incidence , Alprostadil/usage thérapeutique , Alprostadil/administration et posologie , Accident ischémique transitoire/épidémiologie , Accident ischémique transitoire/prévention et contrôle , Accident ischémique transitoire/traitement médicamenteux , Résultat thérapeutique , Angiopathies intracrâniennes/épidémiologie , Accident vasculaire cérébral/épidémiologie , Accident vasculaire cérébral/prévention et contrôle , Vasodilatateurs/usage thérapeutique , Vasodilatateurs/administration et posologie , Sujet âgéRÉSUMÉ
BACKGROUND: Anti-inflammatory therapy with long-term colchicine prevented vascular recurrence in coronary disease. Unlike coronary disease, which is typically caused by atherosclerosis, ischaemic stroke is caused by diverse mechanisms including atherosclerosis and small vessel disease or is frequently due to an unknown cause. We aimed to investigate the hypothesis that long-term colchicine would reduce recurrent events after ischaemic stroke. METHODS: We did a randomised, parallel-group, open-label, blinded endpoint assessed trial comparing long-term colchicine (0·5 mg orally per day) plus guideline-based usual care with usual care only. Hospital-based patients with non-severe, non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack were eligible. The primary endpoint was a composite of first fatal or non-fatal recurrent ischaemic stroke, myocardial infarction, cardiac arrest, or hospitalisation (defined as an admission to an inpatient unit or a visit to an emergency department that resulted in at least a 24 h stay [or a change in calendar date if the hospital admission or discharge times were not available]) for unstable angina. The p value for significance was 0·048 to adjust for two prespecified interim analyses conducted by the data monitoring committee, for which the steering committee and trial investigators remained blinded. The trial was registered at ClinicalTrials.gov (NCT02898610) and is completed. FINDINGS: 3154 patients were randomly assigned between Dec 19, 2016, and Nov 21, 2022, with the last follow-up on Jan 31, 2024. The trial finished before the anticipated number of outcomes was accrued (367 outcomes planned) due to budget constraints attributable to the COVID-19 pandemic. Ten patients withdrew consent for analysis of their data, leaving 3144 patients in the intention-to-treat analysis: 1569 (colchicine and usual care) and 1575 (usual care alone). A primary endpoint occurred in 338 patients, 153 (9·8%) of 1569 patients allocated to colchicine and usual care and 185 (11·7%) of 1575 patients allocated to usual care alone (incidence rates 3·32 vs 3·92 per 100 person-years, hazard ratio 0·84; 95% CI 0·68-1·05, p=0·12). Although no between-group difference in C-reactive protein (CRP) was observed at baseline, patients treated with colchicine had lower CRP at 28 days and at 1, 2, and 3 years (p<0·05 for all timepoints). The rates of serious adverse events were similar in both groups. INTERPRETATION: Although no statistically significant benefit was observed on the primary intention-to-treat analysis, the findings provide new evidence supporting the rationale for anti-inflammatory therapy in further randomised trials. FUNDING: Health Research Board Ireland, Deutsche Forschungsgemeinschaft (German Research Foundation), and Fonds Wetenschappelijk Onderzoek Vlaanderen (Research Foundation Flanders), Belgium.
Sujet(s)
Colchicine , Accident vasculaire cérébral ischémique , Prévention secondaire , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Colchicine/administration et posologie , Colchicine/usage thérapeutique , Hospitalisation/statistiques et données numériques , Accident ischémique transitoire/prévention et contrôle , Accident ischémique transitoire/traitement médicamenteux , Accident vasculaire cérébral ischémique/prévention et contrôle , Infarctus du myocarde/prévention et contrôle , Récidive , Prévention secondaire/méthodes , Accident vasculaire cérébral/prévention et contrôle , Résultat thérapeutiqueRÉSUMÉ
AIMS: Subclinical atrial fibrillation (AF) is associated with increased risk of progression to clinical AF, stroke, and cardiovascular death. We hypothesized that in pacemaker patients requiring dual-chamber rate-adaptive (DDDR) pacing, closed loop stimulation (CLS) integrated into the circulatory control system through intra-cardiac impedance monitoring would reduce the occurrence of atrial high-rate episodes (AHREs) compared with conventional DDDR pacing. METHODS AND RESULTS: Patients with sinus node dysfunctions (SNDs) and an implanted pacemaker or defibrillator were randomly allocated to dual-chamber CLS (n = 612) or accelerometer-based DDDR pacing (n = 598) and followed for 3 years. The primary endpoint was time to the composite endpoint of the first AHRE lasting ≥6 min, stroke, or transient ischaemic attack (TIA). All AHREs were independently adjudicated using intra-cardiac electrograms. The incidence of the primary endpoint was lower in the CLS arm (50.6%) than in the DDDR arm (55.7%), primarily due to the reduction in AHREs lasting between 6 h and 7 days. Unadjusted site-stratified hazard ratio (HR) for CLS vs. DDDR was 0.84 [95% confidence interval (CI), 0.72-0.99; P = 0.035]. After adjusting for CHA2DS2-VASc score, the HR remained 0.84 (95% CI, 0.71-0.99; P = 0.033). In subgroup analyses of AHRE incidence, the incremental benefit of CLS was greatest in patients without atrioventricular block (HR, 0.77; P = 0.008) and in patients without AF history (HR, 0.73; P = 0.009). The contribution of stroke/TIA to the primary endpoint (1.3%) was low and not statistically different between study arms. CONCLUSION: Dual-chamber CLS in patients with SND is associated with a significantly lower AHRE incidence than conventional DDDR pacing.
Sujet(s)
Fibrillation auriculaire , Entraînement électrosystolique , Rythme cardiaque , Accident ischémique transitoire , Pacemaker , Maladie du sinus , Accident vasculaire cérébral , Humains , Femelle , Mâle , Fibrillation auriculaire/physiopathologie , Fibrillation auriculaire/diagnostic , Fibrillation auriculaire/thérapie , Fibrillation auriculaire/épidémiologie , Sujet âgé , Maladie du sinus/thérapie , Maladie du sinus/physiopathologie , Entraînement électrosystolique/méthodes , Accident ischémique transitoire/prévention et contrôle , Accident ischémique transitoire/épidémiologie , Adulte d'âge moyen , Accident vasculaire cérébral/prévention et contrôle , Accident vasculaire cérébral/épidémiologie , Incidence , Résultat thérapeutique , Facteurs temps , Facteurs de risque , Défibrillateurs implantables , Techniques électrophysiologiques cardiaques , Accélérométrie , Sujet âgé de 80 ans ou plusRÉSUMÉ
BACKGROUND: Surgical left atrial appendage (LAA) closure concomitant to open-heart surgery prevents thromboembolism in high-risk patients. Nevertheless, high-level evidence does not exist for LAA closure performed in patients with any CHA2DS2-VASc score and preoperative atrial fibrillation or flutter (AF) status-the current trial attempts to provide such evidence. METHODS: The study is designed as a randomized, open-label, blinded outcome assessor, multicenter trial of adult patients undergoing first-time elective open-heart surgery. Patients with and without AF and any CHA2DS2-VASc score will be enrolled. The primary exclusion criteria are planned LAA closure, planned AF ablation, or ongoing endocarditis. Before randomization, a three-step stratification process will sort patients by site, surgery type, and preoperative or expected oral anticoagulation treatment. Patients will undergo balanced randomization (1:1) to LAA closure on top of the planned cardiac surgery or standard care. Block sizes vary from 8 to 16. Neurologists blinded to randomization will adjudicate the primary outcome of stroke, including transient ischemic attack (TIA). The secondary outcomes include a composite outcome of stroke, including TIA, and silent cerebral infarcts, an outcome of ischemic stroke, including TIA, and a composite outcome of stroke and all-cause mortality. LAA closure is expected to provide a 60% relative risk reduction. In total, 1500 patients will be randomized and followed for 2 years. DISCUSSION: The trial is expected to help form future guidelines within surgical LAA closure. This statistical analysis plan ensures transparency of analyses and limits potential reporting biases. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03724318. Registered 26 October 2018, https://clinicaltrials.gov/study/NCT03724318 . PROTOCOL VERSION: https://doi.org/10.1016/j.ahj.2023.06.003 .
Sujet(s)
Auricule de l'atrium , Fibrillation auriculaire , Procédures de chirurgie cardiaque , Études multicentriques comme sujet , Essais contrôlés randomisés comme sujet , Accident vasculaire cérébral , Humains , Auricule de l'atrium/chirurgie , Fibrillation auriculaire/chirurgie , Fibrillation auriculaire/complications , Accident vasculaire cérébral/prévention et contrôle , Accident vasculaire cérébral/étiologie , Procédures de chirurgie cardiaque/effets indésirables , Facteurs de risque , Résultat thérapeutique , Appréciation des risques , Interprétation statistique de données , Accident ischémique transitoire/prévention et contrôle , Accident ischémique transitoire/étiologie , Mâle , Femelle ,RÉSUMÉ
BACKGROUND AND PURPOSE: This systematic review examines the effectiveness of motivational interviewing (MI) on medication adherence for preventing recurrent stroke and transient ischemic attack (TIA). METHODS: MEDLINE (via PubMed), CINAHL, PsycINFO, CENTRAL, and ClinicalTrials.gov were searched from inception to 12 June 2023. Randomized controlled trials comparing MI with usual care or interventions without MI in participants with any stroke type were identified and summarized descriptively. Primary outcome was medication adherence. Secondary outcomes were quality of life (QoL) and different clinical outcomes. We assessed risk of bias with RoB 2 (revised Cochrane risk-of-bias tool) and intervention complexity with the iCAT_SR (intervention Complexity Assessment Tool for Systematic Reviews). RESULTS: We screened 691 records for eligibility and included four studies published in five articles. The studies included a total of 2751 participants, and three were multicentric. Three studies had a high risk of bias, and interventions varied in complexity. Two studies found significantly improved medication adherence, one at 9 (96.9% vs. 88.2%, risk ratio = 1.098, 95% confidence interval = 1.03-1.17) and one at 12 months (97.0% vs. 95.0%, p = 0.026), but not at other time points, whereas two other studies reported no significant changes. No significant differences were found in QoL or clinical outcomes. CONCLUSIONS: Evidence on MI appears inconclusive for improving medication adherence for recurrent stroke and TIA prevention, with no benefits on QoL and clinical outcomes. There is a need for robustly designed studies and process evaluations of MI as a complex intervention for people with stroke. REGISTRATION: PROSPERO (CRD42023433284).
Sujet(s)
Accident ischémique transitoire , Adhésion au traitement médicamenteux , Entretien motivationnel , Essais contrôlés randomisés comme sujet , Prévention secondaire , Accident vasculaire cérébral , Humains , Accident ischémique transitoire/prévention et contrôle , Accident ischémique transitoire/traitement médicamenteux , Entretien motivationnel/méthodes , Essais contrôlés randomisés comme sujet/méthodes , Accident vasculaire cérébral/prévention et contrôle , Accident vasculaire cérébral/traitement médicamenteux , Prévention secondaire/méthodes , RécidiveRÉSUMÉ
OBJECTIVES: Coptisine (Cop), an alkaloid isolated from Rhizoma Coptidis, has a protective effect against central nervous system diseases such as cerebral ischaemia-reperfusion (IR). Dysregulations in fatty acids metabolism are associated with neuroprotection and neuroinflammation. However, the effect of Cop on fatty acids metabolomics during anti-IR remains unclear. METHODS: Cerebral IR rats were established by middle cerebral artery occlusion, and the therapeutic effect of Cop was evaluated by 2, 3, 5-triphenytetrazolium chloride staining and neurological deficits scores. By liquid chromatography-tandem mass spectrometry (LC-MS/MS), fatty acids metabolomics analysis in ischaemic hemisphere and serum were investigated. RESULTS: We observed Cop (2 mg/kg/qd) was able to reduce cerebral infarct size and ameliorate the neurological function score. Meanwhile decrease in tumour necrosis factor-α (TNF-α), and interleukin-1ß (IL-1ß) after Cop treatment. Compared with control, down-regulation of cyclopentenone PGs (e.g., PGA2, PGJ2, and 15-deoxy- delta-12,14-PGJ2) was observed in cerebral IR, but upregulation of them when followed by Cop treatment. Similarly, we found the ratios of 14,15-dihydroxyeicosatrienoic acid(14,15-DHET)/arachidonic acid and 11,12-DHET/arachidonic acid was lower in cerebral IR injury relative to control, while their ratios were increased after Cop treatment. CONCLUSION: Our results indicated that Cop protect against cerebral IR injury, and its mechanism might be closely associated with antiinflammation and the regulation of arachidonic acid metabolism.
Sujet(s)
Acide arachidonique , Berbérine , Infarctus du territoire de l'artère cérébrale moyenne , Rat Sprague-Dawley , Lésion d'ischémie-reperfusion , Facteur de nécrose tumorale alpha , Animaux , Berbérine/pharmacologie , Berbérine/analogues et dérivés , Acide arachidonique/métabolisme , Mâle , Rats , Infarctus du territoire de l'artère cérébrale moyenne/traitement médicamenteux , Infarctus du territoire de l'artère cérébrale moyenne/métabolisme , Lésion d'ischémie-reperfusion/traitement médicamenteux , Lésion d'ischémie-reperfusion/métabolisme , Lésion d'ischémie-reperfusion/prévention et contrôle , Facteur de nécrose tumorale alpha/métabolisme , Neuroprotecteurs/pharmacologie , Interleukine-1 bêta/métabolisme , Modèles animaux de maladie humaine , Spectrométrie de masse en tandem , Accident ischémique transitoire/traitement médicamenteux , Accident ischémique transitoire/métabolisme , Accident ischémique transitoire/prévention et contrôle , Métabolomique/méthodes , Acides gras/métabolismeSujet(s)
Acide acétylsalicylique , Clopidogrel , Accident ischémique transitoire , Accident vasculaire cérébral ischémique , Antiagrégants plaquettaires , Récidive , Prévention secondaire , Humains , Clopidogrel/administration et posologie , Clopidogrel/effets indésirables , Clopidogrel/usage thérapeutique , Acide acétylsalicylique/administration et posologie , Acide acétylsalicylique/effets indésirables , Acide acétylsalicylique/usage thérapeutique , Accident ischémique transitoire/traitement médicamenteux , Accident ischémique transitoire/prévention et contrôle , Accident vasculaire cérébral ischémique/traitement médicamenteux , Accident vasculaire cérébral ischémique/prévention et contrôle , Antiagrégants plaquettaires/administration et posologie , Antiagrégants plaquettaires/effets indésirables , Antiagrégants plaquettaires/usage thérapeutique , Prévention secondaire/méthodes , Prévention secondaire/normes , Facteurs temps , Association de médicaments , Accident vasculaire cérébral/prévention et contrôle , Accident vasculaire cérébral/étiologie , Facteurs de risque , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: The optimal antithrombotic strategies for patients with atrial fibrillation who experience ischemic stroke (IS) despite direct oral anticoagulant (DOAC) therapy remain inconclusive. This study compared outcomes for patients with DOAC treatment failure who changed or retained their prestroke DOAC. METHODS AND RESULTS: This retrospective cohort study analyzed data from the National Health Insurance Research Database from 2012 to 2020. Patients with atrial fibrillation who experienced IS during DOAC therapy were assigned to either (1) the DOAC-change group: changing prestroke DOAC or (2) the DOAC-retain group: retaining prestroke DOAC. The primary outcome was a composite of recurrent IS and transient ischemic attack. The secondary outcomes included intracranial hemorrhage, major bleeding, systemic thromboembolism, and all-cause death. Propensity score-based inverse probability of treatment weighting was applied to balance the baseline characteristics between the DOAC-change and DOAC-retain groups. The Cox proportional hazards model compared the risk of outcomes between the 2 groups. In total, 1979 patients were enrolled (609 DOAC-change patients and 1370 DOAC-retain patients). The incidence rates of recurrent IS or transient ischemic attack were 7.20 and 6.56 per 100 person-years in the DOAC-change and DOAC-retain groups, respectively (hazard ratio [HR], 1.07 [95% CI, 0.87-1.30]). A nonsignificantly higher incidence rate of intracranial hemorrhage was observed in the DOAC-change group compared with the DOAC-retain group (0.75 versus 0.53 per 100-person-years; HR, 1.49 [95% CI, 0.78-2.83]). The systemic thromboembolism, major bleeding, and death rates were comparable between the DOAC-change and DOAC-retain groups. CONCLUSIONS: Changing prestroke DOAC does not reduce the risk of recurrent cerebral ischemia in patients with atrial fibrillation who develop IS during DOAC therapy. However, future studies should continue to observe the potential trends of increased intracranial hemorrhage risk.
Sujet(s)
Fibrillation auriculaire , Accident ischémique transitoire , Accident vasculaire cérébral ischémique , Accident vasculaire cérébral , Thromboembolie , Humains , Accident ischémique transitoire/épidémiologie , Accident ischémique transitoire/prévention et contrôle , Fibrillation auriculaire/complications , Fibrillation auriculaire/diagnostic , Fibrillation auriculaire/traitement médicamenteux , Accident vasculaire cérébral/épidémiologie , Accident vasculaire cérébral/étiologie , Accident vasculaire cérébral/prévention et contrôle , Accident vasculaire cérébral ischémique/diagnostic , Accident vasculaire cérébral ischémique/épidémiologie , Accident vasculaire cérébral ischémique/prévention et contrôle , Études rétrospectives , Anticoagulants/usage thérapeutique , Hémorragie/induit chimiquement , Hémorragie/épidémiologie , Hémorragies intracrâniennes/induit chimiquement , Hémorragies intracrâniennes/épidémiologie , Hémorragies intracrâniennes/complications , Administration par voie oraleRÉSUMÉ
BACKGROUNDS: Dual-antiplatelet therapy (DAPT) with aspirin and clopidogrel for minor strokes or TIAs has been demonstrated in several RCTs. Whether drug selection for mono-antiplatelet therapy (MAPT) following DAPT may influence stroke recurrence has not been clarified, especially for patients with intracranial atherosclerosis stenosis (ICAS). The Thrombelastography Platelet Mapping (TEG-PM) assay claimed to be capable of monitoring platelet function secondary to antiplatelet therapy. PURPOSE: The aim of this study was to investigate the preventive role of TEG-PM in individualized drug selection for MAPT following DAPT in patients with minor stroke or TIA. METHODS: We retrospectively reviewed our patient database to identify individuals with minor stroke or TIA between February 2019 and July 2022. Patients were divided into ICAS and non-ICAS groups, and the efficacy and safety of TEG-PM-guided MAPT for stroke prevention after minor stroke or TIA were investigated in each group. RESULTS: ICAS patients with TEG-PM-guided MAPT had lower rates of recurrent stroke than patients without TEG-PM guidance during a mean follow-up period of 18.1 months (6.3% vs 15.2%; p = 0.04). Patients without ICAS also tended to benefit from TEG-PM-guided MAPT with lower rates of stroke recurrence (2.6% vs 8.7%; p = 0.02). No difference in the safety outcome of any bleeding events was observed in patients with TEG-PM-guided MAPT and those without (ICAS group, 2.1% vs 3.0%; p = 0.68; non-ICAS group, 1.3% vs 2.3%; p = 0.79). CONCLUSION: The TEG-PM could be a tangible preprocessing in drug selection for MAPT following DAPT in patients with minor strokes or TIAs, especially for those with non-stented ICASs.
Sujet(s)
Accident ischémique transitoire , Accident vasculaire cérébral , Humains , Antiagrégants plaquettaires/usage thérapeutique , Antiagrégants plaquettaires/effets indésirables , Accident ischémique transitoire/traitement médicamenteux , Accident ischémique transitoire/prévention et contrôle , Thromboélastographie , Études rétrospectives , Association de médicaments , Accident vasculaire cérébral/traitement médicamenteux , Accident vasculaire cérébral/prévention et contrôleRÉSUMÉ
BACKGROUND: Following regulatory approval, medical devices may be used "off-label." Patent foramen ovale (PFO) closure is indicated to reduce recurrent stroke but has been proposed for other indications, including migraine, transient ischemic attack, and diving decompression illness. We sought to evaluate PFO closure rates and indications relative to the timing of regulatory approval and publication of key randomized trials. METHODS: We performed a retrospective cohort study using the OptumLabs Data Warehouse of US commercial insurance enrollees from 2006 to 2019. We quantified PFO closure among individuals with ≥2 years of preprocedure coverage to establish indications, classified hierarchically as stroke/systemic embolism, migraine, transient ischemia attack, or other. RESULTS: We identified 5315 patients undergoing PFO closure (51.8% female, 29.2%≥60 years old), which increased from 4.75 per 100â 000 person-years in 2006 to 6.60 per 100â 000 person-years in 2019. Patients aged ≥60 years accounted for 29.2% of closures. Procedure volumes corresponded weakly with supportive clinical publications and device approval. Among patients with PFO closure, 58.6% underwent closure for stroke/systemic embolism, 10.2% for transient ischemia attack, 8.8% for migraine, and 22.4% for other indications; 17.6% of patients had atrial fibrillation at baseline; and 11.9% developed atrial fibrillation postprocedure. Those aged ≥60 years and male were less likely to undergo closure for migraine than stroke/systemic embolism. CONCLUSIONS: From 2006 to 2019, PFO closure use was consistently low and corresponded weakly with clinical trial publications and regulatory status. Nearly half of patients underwent PFO closure for indications unapproved by the Food and Drug Administration. Regulators and payers should coordinate mechanisms to promote utilization for approved indications to ensure patient safety and should facilitate clinical trials for other possible indications.
Sujet(s)
Fibrillation auriculaire , Embolie , Foramen ovale perméable , Accident ischémique transitoire , Migraines , Accident vasculaire cérébral , Humains , Mâle , Femelle , Adulte d'âge moyen , Foramen ovale perméable/chirurgie , Études rétrospectives , Résultat thérapeutique , Cathétérisme cardiaque , Accident vasculaire cérébral/diagnostic , Accident vasculaire cérébral/épidémiologie , Accident vasculaire cérébral/prévention et contrôle , Accident ischémique transitoire/diagnostic , Accident ischémique transitoire/étiologie , Accident ischémique transitoire/prévention et contrôle , Prévention secondaire/méthodes , IschémieRÉSUMÉ
BACKGROUND: Patients with minor ischemic stroke or transient ischemic attacks (TIAs) are often treated with dual antiplatelet therapy regimens as part of secondary stroke prevention. Clopidogrel, an antiplatelet used in these regimens, is metabolized into its active form by the CYP2C19 enzyme. Patients with loss of function (LOF) mutations in CYP2C19 are at risk for poorer secondary outcomes when prescribed clopidogrel. AIMS: We aimed to determine the cost-effectiveness of three different treatment antiplatelet regimens in ischemic stroke populations with minor strokes or TIAs and how these treatment regimens are influenced by the LOF prevalence in the population. METHODS: Markov models were developed to look at the cost-effectiveness of empiric treatment with aspirin and clopidogrel versus empiric treatment with aspirin and ticagrelor, versus genotype-guided therapy for either 21 or 30 days. Effect ratios were obtained from the literature, and incidence rates and costs were obtained from the national data published by the Singapore Ministry of Health. The primary endpoints were the incremental cost-effectiveness ratios (ICERs). RESULTS: Empiric treatment with aspirin and ticagrelor was the most cost-effective treatment. Genotype-guided therapy was more cost-effective than empiric aspirin and clopidogrel if the LOF was above 48%. Empiric ticagrelor and aspirin was cost saving when compared to genotype-guided therapy. Results in models of dual antiplatelet therapy for 30 days were similar. CONCLUSION: This study suggests that in patients with minor stroke and TIA planned for dual antiplatelet regimens, empiric ticagrelor and aspirin is the most cost-effective treatment regimen. If ticagrelor is not available, genotype-guided therapy is the most cost-effective treatment regimen if the LOF prevalence in the population is more than 48%.
Sujet(s)
Accident ischémique transitoire , Accident vasculaire cérébral ischémique , Accident vasculaire cérébral , Humains , Ticagrélor/usage thérapeutique , Acide acétylsalicylique/usage thérapeutique , Accident vasculaire cérébral/traitement médicamenteux , Accident vasculaire cérébral/prévention et contrôle , Antiagrégants plaquettaires/usage thérapeutique , Clopidogrel/usage thérapeutique , Accident ischémique transitoire/traitement médicamenteux , Accident ischémique transitoire/prévention et contrôle , Cytochrome P-450 CYP2C19/génétique , Cytochrome P-450 CYP2C19/usage thérapeutique , Analyse coût-bénéfice , Accident vasculaire cérébral ischémique/traitement médicamenteux , Résultat thérapeutique , Association de médicamentsRÉSUMÉ
CONTEXT: A healthy, 22-year-old, male NCAA Division I baseball shortstop was experiencing confusion, chest pain, and tightness during an off-season intersquad scrimmage. The patient did not have any significant medical history or mechanism of head injury. After initial evaluation from the athletic trainer, the patient's cognitive status began to quickly decline. The emergency action plan was put in place rapidly and referred the patient to the local emergency clinic. CASE PRESENTATION: Upon arrival at the emergency department, an electrocardiogram was performed to rule out myocardial infarction or stroke. The first electrocardiogram results returned negative for any cardiac pathology, but a stroke alert was called. The patient was then transported to a level II trauma center due to continual cognitive decline. The patient was diagnosed with transient ischemic attack (TIA) secondary to an undiagnosed patent foramen ovale (PFO) that would later be diagnosed with further evaluation 2 months after the initial TIA incident. After multiple diagnostic and laboratory tests, the PFO went undetected until a 2D echocardiogram was performed and evaluated by a cardiologist. MANAGEMENT AND OUTCOMES: After the confirmation of the congenital defect, surgical intervention was performed to correct the PFO using catheterization. Despite multiple preparticipation examinations, electrocardiograms, and examination of past family history, the PFO went undetected until the patient experienced symptoms of TIA. The discovery of PFO in this 22-year-old athletic individual is unusual because traditional screening techniques (electrocardiogram and preparticipation examinations) failed to detect the congenital defect. CONCLUSIONS: Due to the emergent and timely actions of the athletic trainer, the patient has made a full recovery and is able to compete fully in athletic events. This case study amplifies the need for athletic trainers at all sporting events, updated and reviewed emergency action plans, rapid recognition of TIA in athletic individuals, and return-to-play protocol for an athletic individual after TIA.
Sujet(s)
Baseball , Foramen ovale perméable , Accident ischémique transitoire , Accident vasculaire cérébral , Humains , Mâle , Jeune adulte , Adulte , Accident ischémique transitoire/diagnostic , Accident ischémique transitoire/étiologie , Accident ischémique transitoire/prévention et contrôle , Accident vasculaire cérébral/diagnostic , Accident vasculaire cérébral/étiologie , Accident vasculaire cérébral/prévention et contrôle , Foramen ovale perméable/complications , Foramen ovale perméable/diagnostic , Foramen ovale perméable/chirurgie , Athlètes , Résultat thérapeutiqueRÉSUMÉ
Globally, up to 1·5 million individuals with ischaemic stroke or transient ischaemic attack can be newly diagnosed with atrial fibrillation per year. In the past decade, evidence has accumulated supporting the notion that atrial fibrillation first detected after a stroke or transient ischaemic attack differs from atrial fibrillation known before the occurrence of as stroke. Atrial fibrillation detected after stroke is associated with a lower prevalence of risk factors, cardiovascular comorbidities, and atrial cardiomyopathy than atrial fibrillation known before stroke occurrence. These differences might explain why it is associated with a lower risk of recurrence of ischaemic stroke than known atrial fibrillation. Patients with ischaemic stroke or transient ischaemic attack can be classified in three categories: no atrial fibrillation, known atrial fibrillation before stroke occurrence, and atrial fibrillation detected after stroke. This classification could harmonise future research in the field and help to understand the role of prolonged cardiac monitoring for secondary stroke prevention with application of a personalised risk-based approach to the selection of patients for anticoagulation.
Sujet(s)
Fibrillation auriculaire , Encéphalopathie ischémique , Accident ischémique transitoire , Accident vasculaire cérébral ischémique , Accident vasculaire cérébral , Humains , Accident ischémique transitoire/prévention et contrôle , Accident vasculaire cérébral/complications , Accident vasculaire cérébral/prévention et contrôle , Fibrillation auriculaire/diagnostic , Encéphalopathie ischémique/complications , Accident vasculaire cérébral ischémique/complications , Anticoagulants/usage thérapeutiqueRÉSUMÉ
OBJECTIVES: The American Heart Association/American Stroke Association and the American Association of Clinical Endocrinology provided guidelines for patients with transient ischemic attacks or strokes (TIA/stroke) and diabetes mellitus with the use of glucose-lowering agents (GLA) effective in preventing major adverse cardiovascular events (MACE). This review evaluated GLA for specific differences in TIA/stroke prevention. METHODS: Previous reviews and meta-analyses were evaluated for outcomes of MACE, cardiovascular death (CVD), hospitalization for heart failure, and TIA/stroke. The GLA were glucagon-like peptide 1-receptor agonists (GLP-1RA, 6-trials, n = 46 541), sodium-glucose transport 2 inhibitors (SGLT2i, 5-trials, n = 46 959), insulin-providing regimens (IP, 4-trials, n = 26 223), and thiazolidinediones (TZD, 1-trial, n = 5238). RESULTS: There were reductions in MACE for each class. Relative risk (rr) reductions for TIA/stroke were found with GLP-1RA (rr = 0.840, 95% CI: 0.759, 0.936, P =.001) but not with SGLT2i, IP, or TZD. Cardiovascular deaths were decreased with GLP-1RA (rr = 0.873, CI: 0.804, 0.947, P =.001) and SGLT2i (rr = 0.835, CI: 0.706, 0.987, P =.034), but not with TZD or IP. Hospitalizations for heart failure were decreased only with SGLT2i (rr = 0.699, CI: 0.626, 0.781, P <.001). Increased CVD correlated with aggressive lowering of A1c (r = -0.611, P =.012) and showed a trend with the relative risk of hypoglycemia (r = 0.447, P =.08). For GLP-1RA, there was no increase in hypoglycemia and a direct correlation with a decreased rr for stroke with decreases in A1c (r = 0.917, P =.010). CONCLUSION: Improvements in A1c with GLP-1RA were associated with stroke prevention in patients with diabetes and with TIA or stroke. Reductions in cardiovascular mortality include therapy with GLP-1RA and SGLT2i. Aggressive lowering of A1c, however, was associated with increased CVD.
Sujet(s)
Maladies cardiovasculaires , Diabète de type 2 , Défaillance cardiaque , Hypoglycémie , Accident ischémique transitoire , Inhibiteurs du cotransporteur sodium-glucose de type 2 , Accident vasculaire cérébral , Humains , Hypoglycémiants/usage thérapeutique , Diabète de type 2/complications , Diabète de type 2/traitement médicamenteux , Hémoglobine glyquée , Accident ischémique transitoire/prévention et contrôle , Accident ischémique transitoire/induit chimiquement , Accident ischémique transitoire/complications , Inhibiteurs du cotransporteur sodium-glucose de type 2/usage thérapeutique , Récepteur du peptide-1 similaire au glucagon , Défaillance cardiaque/induit chimiquement , Défaillance cardiaque/complications , Défaillance cardiaque/traitement médicamenteux , Hypoglycémie/induit chimiquement , Accident vasculaire cérébral/prévention et contrôle , Accident vasculaire cérébral/induit chimiquement , Accident vasculaire cérébral/complications , Glucose/usage thérapeutique , Maladies cardiovasculaires/prévention et contrôle , Maladies cardiovasculaires/complicationsSujet(s)
Acide acétylsalicylique , Accident ischémique transitoire , Antiagrégants plaquettaires , Accident vasculaire cérébral , Humains , Acide acétylsalicylique/administration et posologie , Acide acétylsalicylique/effets indésirables , Acide acétylsalicylique/usage thérapeutique , Association de médicaments , Accident ischémique transitoire/traitement médicamenteux , Accident ischémique transitoire/prévention et contrôle , Antiagrégants plaquettaires/administration et posologie , Antiagrégants plaquettaires/effets indésirables , Antiagrégants plaquettaires/usage thérapeutique , Accident vasculaire cérébral/traitement médicamenteux , Accident vasculaire cérébral/prévention et contrôleRÉSUMÉ
Antiplatelet therapy is the first-line management for noncardioembolic transient ischemic attack (TIA) and acute ischemic stroke (IS). Herein, we review the safety and efficacy of antiplatelet therapies in patients with IS and TIA, primarily focusing on the acute stage. We discuss current antiplatelet monotherapy and the factors influencing efficacy and continuation rate according to clinical trial data. Aspirin remains the most commonly used first-line antiplatelet agent for preventing noncardioembolic stroke recurrence, and clopidogrel, cilostazol, and ticagrelor are feasible alternatives. Various short-term dual antiplatelet therapies (including clopidogrel-aspirin and ticagrelor-aspirin combination therapy) for minor stroke and high-risk TIA are also reviewed. For selected patients with specific stroke etiologies, short-term dual antiplatelet therapy with aspirin combined with clopidogrel or ticagrelor can significantly reduce the risk of stroke. However, insufficient evidence supports the benefits of triple antiplatelet therapy for recurrent noncardioembolic stroke prevention, and this treatment substantially increases the rate of bleeding complications. Keyword: antiplatelet therapy, acute ischemic stroke, secondary prevention, transient ischemic attack.
Sujet(s)
Accident ischémique transitoire , Accident vasculaire cérébral ischémique , Accident vasculaire cérébral , Humains , Prévention secondaire , Antiagrégants plaquettaires/effets indésirables , Accident ischémique transitoire/complications , Accident ischémique transitoire/traitement médicamenteux , Accident ischémique transitoire/prévention et contrôle , Ticagrélor , Clopidogrel , Accident vasculaire cérébral/traitement médicamenteux , Accident vasculaire cérébral/étiologie , Accident vasculaire cérébral/prévention et contrôle , Infarctus cérébral , Acide acétylsalicylique/usage thérapeutiqueRÉSUMÉ
Healthy living with physical activity, healthy eating habits, no smoking, and no alcohol overuse have an important role in primary and secondary stroke prevention. Further secondary prevention depends on type and cause of stroke or TIA. After intracerebral bleeding, ischemic stroke or TIA, preventive pharmacological therapies include antihypertensive drugs. After ischemic stroke or TIA, treatment with antithrombotics (oral anticoagulants or antiplatelets) and statins is recommended. In stroke due to unusual causes, the pharmacological preventive treatment described above may need modification. For symptomatic carotid stenosis, carotid surgery is recommended, preferably within the first 14 days after onset. A surgical preventive treatment is closure of patent foramen ovale in patients aged 18-60 years with ischemic stroke of unknown cause.
Sujet(s)
Accident ischémique transitoire , Accident vasculaire cérébral ischémique , Accident vasculaire cérébral , Humains , Accident ischémique transitoire/prévention et contrôle , Accident vasculaire cérébral/étiologie , Accident vasculaire cérébral/prévention et contrôle , Hémorragie cérébrale , Prévention secondaireRÉSUMÉ
AIMS: Heart failure (HF) is a risk factor for major adverse events in atrial fibrillation (AF). Whether this risk persists on non-vitamin K antagonist oral anticoagulants (NOACs) and varies according to left ventricular ejection fraction (LVEF) is debated. METHODS AND RESULTS: We investigated the relation of HF in the ETNA-AF-Europe registry, a prospective, multicentre, observational study with an overall 4-year follow-up of edoxaban-treated AF patients. We report 2-year follow-up for ischaemic stroke/transient ischaemic attack (TIA)/systemic embolic events (SEE), major bleeding, and mortality. Of the 13 133 patients, 1854 (14.1%) had HF. Left ventricular ejection fraction was available for 82.4% of HF patients and was <40% in 671 (43.9%) and ≥40% in 857 (56.1%). Patients with HF were older, more often men, and had more comorbidities. Annualized event rates (AnERs) of any stroke/SEE were 0.86%/year and 0.67%/year in patients with and without HF. Compared with patients without HF, those with HF also had higher AnERs for major bleeding (1.73%/year vs. 0.86%/year) and all-cause death (8.30%/year vs. 3.17%/year). Multivariate Cox proportional models confirmed HF as a significant predictor of major bleeding [hazard ratio (HR) 1.65, 95% confidence interval (CI): 1.20-2.26] and all-cause death [HF with LVEF <40% (HR 2.42, 95% CI: 1.95-3.00) and HF with LVEF ≥40% (HR 1.80, 95% CI: 1.45-2.23)] but not of ischaemic stroke/TIA/SEE. CONCLUSION: Anticoagulated patients with HF at baseline featured higher rates of major bleeding and all-cause death, requiring optimized management and novel preventive strategies. NOAC treatment was similarly effective in reducing risk of ischaemic events in patients with or without concomitant HF.